Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from six study groups Journal Article

  

Authors:	Steyerberg, E. W.; Keizer, H. J.; Fosså, S. D.; Sleijfer, D. T.; Toner, G. C.; Schraffordt Koops, H.; Mulders, P. F. A.; Messemer, J. E.; Ney, K.; Donohue, J. P.; Bajorin, D.; Stoter, G.; Bosl, G. J.; Habbema, J. D. F.
Article Title:	Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from six study groups
Abstract:	Purpose: To develop a statistical model that predicts the histology (necrosis, mature teratoma, or cancer) after chemotherapy for metastatic nonseminomatous germ cell tumor (NSGCT). Patients and Methods: An international data was collected comprising individual patient data from six study groups. Logistic regression analysis was used to estimate the probability of necrosis and the ratio of cancer and mature teratoma. Results: Of 556 patients, 250 (45%) had necrosis at resection, 236 (42%) had mature teratoma, and 70 (13%) had cancer. Predictors of necrosis were the absence fo teratoma elements in the primary tumor, prechemotherapy normal alfa-fetoprotein (AFP), normal human chorionic gonadotropin (HCG), and elevated lactate dehydrogenase (LDH) levels, a small prechemotherapy or postchemotherapy mass, and a large shrinkage of the mass during chemotherapy. Multivariate combination of predictors yielded reliable models (goodness-of-fit tests, P > .20), which discriminated necrosis well from other histologies (area under the receiver operating characteristics (ROC) curve, .84), but which discriminated cancer only reasonably from mature teratoma (area, .66). Internal and external validation confirmed these findings. Conclusion: The validated models estimated with high accuracy the histology at resection, especially necrosis, based on well-known and readily available predictors. The predicted probabilities may help to chose between immediate resection of a residual mass or follow-up, taking into account the expected benefits and risks of resection, feasibility of frequent follow-up, the follow-up, the financial costs, and the patient's individual preferences.
Keywords:	cisplatin; chemotherapy; lymphadenectomy; vinblastine; prognostic factors; bleomycin; surgery; teratoma; testicular cancer; stage-iii; combination
Journal Title:	Journal of Clinical Oncology
Volume:	13
Issue:	5
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	1995-05-01
Start Page:	1177
End Page:	1187
Language:	English
ACCESSION:	WOS:A1995QV95100019
DOI:	10.1200/jco.1995.13.5.1177
PROVIDER:	wos
PUBMED:	7537801
Notes:	Article -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/133749